Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 12, 2022
Reply to Viel
Christopher Recknor, Scott G Hansen, Norman B Gaylis, et al.
JBMR Plus
|
September 22, 2025
Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density
Timo Damm, Cesar Libanati, Jaime Peña, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 9, 2009
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent
Felicia Cosman, Robert A Wermers, Christopher Recknor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 22, 2022
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Norman B Gaylis, Angela Ritter, Scott A Kelly, et al.
Clinical Therapeutics
|
May 19, 2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study
Ronald Emkey, Pierre D Delmas, Michael Bolognese, et al.
Bone
|
July 5, 2015
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology
Philippe Zysset, Dieter Pahr, Klaus Engelke, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 31, 2012
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial
Jacques P Brown, Christian Roux, Ove Törring, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
June 30, 2021
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
Jacques P Brown, Klaus Engelke, Tony M Keaveny, et al.
Menopause (New York, N.Y.)
|
September 27, 2012
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture
James A Simon, Christopher Recknor, Alfred H Moffett, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 12, 2022
Reply to Viel
Christopher Recknor, Scott G Hansen, Norman B Gaylis, et al.
JBMR Plus
|
September 22, 2025
Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density
Timo Damm, Cesar Libanati, Jaime Peña, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 9, 2009
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent
Felicia Cosman, Robert A Wermers, Christopher Recknor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 22, 2022
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Norman B Gaylis, Angela Ritter, Scott A Kelly, et al.
Clinical Therapeutics
|
May 19, 2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study
Ronald Emkey, Pierre D Delmas, Michael Bolognese, et al.
Bone
|
July 5, 2015
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology
Philippe Zysset, Dieter Pahr, Klaus Engelke, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 31, 2012
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial
Jacques P Brown, Christian Roux, Ove Törring, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
June 30, 2021
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
Jacques P Brown, Klaus Engelke, Tony M Keaveny, et al.
Menopause (New York, N.Y.)
|
September 27, 2012
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture
James A Simon, Christopher Recknor, Alfred H Moffett, et al.
Page
of 1